Parathyroid hormone analogues and methods of use
OwnerPaul Morley, Martin Stogniew +3inventors
InventorsPaul Morley, Martin Stogniew, Brian MacDonald, Gene Scott Merutka, Nagesh Palepu
Life of this patent
Estimating the term…
Abstract
The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic profile and maintained adenylate cyclase activity, while simultaneously reducing undesirable side effects.
Claims52
A method of treating a bone deficit disorder in a subject while reducing side effects associated with the administration of a parathyroid hormone, comprising administering to the subject a parathyroid hormone peptide analog or other peptide with a narrow therapeutic window in an effective dose for the subject, wherein the effective dose for the subject is determined based on the weight of the subject, and wherein there are multiple effective dosages for subjects presenting with different weights, and further wherein the effective dose is calculated based on a predetermined weight cutoff.
A pharmaceutical composition comprising a unit dosage form of a therapeutically effective amount of a parathyroid hormone (PTH) peptide analogue in a dosage determined by a patient's weight and presentation of symptoms, and a pharmaceutically acceptable excipient, diluent, or carrier, or combinations thereof, wherein the pharmaceutical composition administered results in an effective pharmacokinetic profile and maintained adenylate cyclase activity, while simultaneously reducing undesirable side effects associated with the administration of a PTH.
An aqueous pharmaceutical solution, comprising Ostabolin-C in a concentration of about 100-500 ug/ml;
- which comprises ethanol and water;
- wherein said solution has a pH of between 6.0-8.0, and wherein the solution is sterile and ready for parenteral administration to a human patient.
An aqueous pharmaceutical solution, comprising Ostabolin-C in a concentration of about 100-500 ug/ml;
- which has an increased bioavailability, and which further comprises propylene and water;
- wherein said solution has a pH of between 6.0-8.0, and wherein the solution is sterile and ready for parenteral administration to a human patient.
Dependencies are inferred from the claim text.